CAMP4 pairs $124.5m cash pile with widening trial approvals for SYNGAP1 candidate
Third-quarter results show a funded runway into 2028 as regulators in the UK, EU, Australia and Argentina clear sites for the CMP-002 study.
CAMP4 Therapeutics ended the third quarter with $124.5 million in cash, a balance that includes the closing of a $50.1 million private placement. The company reported the figure alongside its quarterly results on 5 November 2026, together with a net loss of $29.0 million for the period.
The title of the company's results announcement says that cash position extends its runway to the end of 2028. The facts available to CompePharma do not include a breakdown of planned spending, so how much of that period is earmarked for CMP-002 specifically is unclear.
CMP-002 is being tested in SYNGAP1-related disorder in the Phase 1/2 ASCEND study. The UK's Medicines and Healthcare products Regulatory Agency authorised study sites in September, and several EU regulators and ethics committees did the same in October. Authorisations granted in July by Australian and Argentine authorities were already in place.
CAMP4 said it still expects to dose its first patient by the end of 2026. The company did not describe in the material reviewed how many sites are covered by each approval or when each country will begin enrolment.
Why it matters
- The private placement and the runway to end-2028 give CAMP4 funding that stretches well beyond its first-dosing target, though dilution terms were not disclosed in the material reviewed.
- With four jurisdictions now cleared, ASCEND can in principle start up across several regions, which will test site activation and safety-reporting set-up.
- Context: in multinational early-phase studies, approval timing often differs by country, so authorisation does not mean every site opens at once.
- The next checkpoint for this rare neurodevelopmental programme is first-patient dosing, which the company has guided to year-end 2026.
Company's press release (SEC filing): Camp4 Therapeutics Corp ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
IRulya Therapeutics reports $105.2M cash as LAM-001 Phase 2 readouts approach
Cerenome reports first CNSide revenue and completes enrolment in Phase 2 glioblastoma trial
BeyondSpring wins FDA Fast Track for plinabulin plus docetaxel in post-immunotherapy NSCLC
Valneva: 94% of adults still seroresponders five years after single IXCHIQ dose
GH Research posts $46.6M nine-month loss as GH001 depression programme nears pivotal stage
